Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Acute Exacerbation of Respiratory Failure
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of the study is to compare the efficacy and tolerance of autotitrating non-invasive ventilation (NIV) versus standard NIV in patients admitted to hospital with acute exacerbation of chronic respiratory failure.
The investigators hypothesise that autotitrating NIV will ventilate patients with acute exacerbations of chronic respiratory failure as effectively as standard NIV.
| Condition | Intervention |
|---|---|
|
Respiratory Failure Neuromuscular Disease Chest Wall Disorder Chronic Obstructive Pulmonary Disease Obesity Hypoventilation Syndrome |
Device: AutoVPAP™ Device: VPAPIIIST-A™ |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Autotitrating Non-invasive Ventilation (NIV) Versus Standard NIV; a Randomised Crossover Trial in Patients With Acute Exacerbation of Chronic Respiratory Failure |
- pH at 1+ hour [ Time Frame: 1 hour ] [ Designated as safety issue: Yes ]pH of arterial blood after 1 hour of treatment with non-invasive ventialtion compared baseline value
- pH at 4+ hours [ Time Frame: 4+ hours of NIV treatment ] [ Designated as safety issue: Yes ]pH of arterial blood after 4 hours of treatment with non-invasive ventialtion compared to baseline value
- Respiratory Rate at 1+ hour [ Time Frame: 1+ hour of NIV treatment ] [ Designated as safety issue: Yes ]Respiratory rate after 1 hour of treatment with non-invasive ventilation compared to baseline value
- Respiratory rate at 4+ hours [ Time Frame: 4+ hours of NIV treatment ] [ Designated as safety issue: Yes ]Respiratory rate after 4 hours of treatment with non-invasive ventilation compared to baseline value
- overnight mean transcutaneous carbon dioxide [ Time Frame: 24 hours ] [ Designated as safety issue: No ]mean overnight transcutaneous carbon dioxide during sleep period
- PaCO2 at 1+ hours [ Time Frame: 1+ hours of NIV treatment ] [ Designated as safety issue: No ]Carbon dixoide level of arterial blood after 1 hour of treatment with non-invasive ventilation compared to baseline
- PaCO2 at 4+ hours [ Time Frame: 4+ hours of NIV treatment ] [ Designated as safety issue: No ]Carbon dioxide level in arterial blood after 4 hours of treatment with non-invasive ventilation compared to baseline value
- PaO2 at 1+ hour [ Time Frame: 1+ hour of NIV treatment ] [ Designated as safety issue: Yes ]Oxygen level in arterial blood after 1 hour of treatment with non-invasive ventilation compared to baseline value
- PaO2 at 4+ hours [ Time Frame: 4+ hours of NIV treatment ] [ Designated as safety issue: Yes ]Oxygen level in arterial blood after 4+ hours of treatment with non-invasive ventilation compared to baseline value
| Estimated Enrollment: | 20 |
| Study Start Date: | August 2010 |
| Estimated Study Completion Date: | March 2013 |
| Estimated Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: autotitrating NIV
approximately 24 hours using autotitrating non-invasive ventilation for as many hours as possible whilst an inpatient in hospital
|
Device: AutoVPAP™
Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
Other Names:
|
|
Active Comparator: Standard non-invasive ventilation
approximately 24 hours using standard non-invasive ventilation for as many hours as possible whilst an inpatient in hospital.
|
Device: VPAPIIIST-A™
Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
Other Names:
|
Detailed Description:
The aim of the study is to compare the effect of two types of noninvasive ventilator (a small machine that assists breathing) in patients admitted to hospital with a sudden worsening of their existing breathing insufficiency, including an increase of carbon dioxide in the blood (hypercapnia) and acidity of the blood. Noninvasive ventilation (NIV) is standard therapy for patients with acute hypercapnic exacerbations (sudden worsening of existing breathing insufficiency) of both chronic obstructive pulmonary disease (COPD) and nonCOPD patients.
The most common type of NIV is bilevel pressure support which assists patient breathing by delivering different levels of air pressure during inspiration and expiration via a mask covering the nose or nose and mouth. Standard bilevel NIV (VPAP™) has been further developed to create a new automatically adjusting NIV (AutoVPAP™). Automatically adjusting NIV varies the inspiratory air pressure according to the airflow rates generated by the patient. This may improve patient comfort, hours of NIV use and recovery time.
Patients over the age of 18 admitted to Royal Brompton Hospital respiratory ward will be considered for entry into this randomised crossover study. If eligible for inclusion and willing to take part patients will be setup on automatically adjusting NIV or standard NIV, assigned in random order. After 24 hours on the first NIV the patient will be swapped to the alternative NIV for a further 24 hours of treatment.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients admitted or transferred to Royal Brompton Hospital with acute exacerbation of chronic respiratory failure, or inpatients who suffer a deterioration in respiratory status, defined as 7.25 < pH < 7.35, PaCO2 > 6.0kPa, and respiratory rate > 20bpm
Exclusion Criteria:
- < 18 years old
- pH < 7.25
- need for immediate intubation
- uncontrolled cardiac failure
- hypotensive (systolic blood pressure < 90mmHg)
- acute myocardial infarction
- acute dysrhythmia
- other system failure (e.g. acute renal failure, liver failure)
- moderate or severe bulbar weakness
- inability to understand rationale and/or consent form for study
Contacts and Locations| United Kingdom | |
| Royal Brompton Hospital | |
| London, United Kingdom, SW3 6NP | |
| Principal Investigator: | Anita Simonds, MD, FRCP | Royal Brompton & Harefield Hospital NHS Trust |
More Information
No publications provided
| Responsible Party: | Dr Anita Simonds, Consultant in Respiratory Medicine, Royal Brompton & Harefield Hospital NHS Trust |
| ClinicalTrials.gov Identifier: | NCT01174316 History of Changes |
| Other Study ID Numbers: | 10/H0808/56, R&D No. 2010LF008B, CI/2010/0027 |
| Study First Received: | August 2, 2010 |
| Last Updated: | March 21, 2012 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Keywords provided by ResMed:
|
Acute exacerbation Respiratory insufficiency Respiratory failure Hypercapnia Hypoventilation |
Sleep Hypoxia Titration Non Invasive Ventilation |
Additional relevant MeSH terms:
|
Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Neuromuscular Diseases Obesity Obesity Hypoventilation Syndrome Hypoventilation Respiratory Insufficiency Lung Diseases, Obstructive Respiratory Tract Diseases Nervous System Diseases Overnutrition |
Nutrition Disorders Overweight Body Weight Signs and Symptoms Sleep Apnea, Obstructive Sleep Apnea Syndromes Apnea Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Signs and Symptoms, Respiratory |
ClinicalTrials.gov processed this record on May 23, 2013